A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma

This first-time in human, single-arm, open-label multicentre Phase I/II study will evaluate the safety, tolerability, antitumour activity, cellular kinetics, pharmacodynamics, and immunogenicity of AZD5851 in adult participants with GPC3+ advanced/recurrent HCC, where at least one line of prior therapy has failed/or was intolerable, or participant/investigator decision.

Sponsor

AstraZeneca

Status of enrollment

Accepting new patients

Ages Eligible for Study

Adults aged 18 and older

Genders Eligible for Study

Female and Male

Disease indication

Hepatocellular Carcinoma, Liver Cancer

Principal Investigator

Bridget Keenan, MD, PhD

Contact

Annie Deng

[email protected]

 

Additional study eligibility details can be found at UCSF Clinical Trials.